Neuromodulator / Hugel
Letybo
LetibotulinumtoxinA and the distinction between investigator, patient and composite response.
Product Atlas · September 2026
The exact product comes first
Scope of this monograph#
Clinical summary: UK Letybo 50 units. German labeling and Australian registration are separately identified.
Clinical statements below summarize the attached documents. They are not a complete prescribing label. Match the exact local product and current instructions to the clinical decision.
Composition & formulation#
The UK 50-unit vial contains botulinum toxin type A as a powder for reconstitution.[2]
How it works#
The toxin cleaves SNAP-25 and inhibits acetylcholine release. Neuromuscular transmission subsequently recovers.[5]
Indications & treatment areas#
The December 2025 UK SmPC covers moderate-to-severe glabellar lines at maximum frown in adults under 75 with important psychological impact.[2]
Application considerations#
Product-specific intramuscular administration and reconstitution are required. Other toxin units are not interchangeable; treatments must be at least three months apart.[2]
Contraindications & precautions#
Relevant hypersensitivity, generalised muscle-activity disorders, and acute infection or inflammation at planned injection sites are contraindications.[2]
Adverse effects & safety#
Ptosis, local reactions and rare hypersensitivity or distant toxin effects require recognition. Dysphagia or breathing problems need immediate medical assessment.[2]
Duration & follow-up#
The phase III study reported a median onset of three days and mean first retreatment around 127 days, with substantial variability.[6]
Distinctions that matter#
A composite response required agreement between investigator and patient. Its 64.7% rate cannot be directly ranked against another trial's single-observer response.[6]
Four markets. Separate evidence.#
Documents below identify what has been attached in this research edition. “Source needed” means unverified here; it is not a statement that a product is unapproved.
German Fachinformation includes the under-75 glabellar indication.[3]
UK SmPC updated December 2025.[2]
US label for letibotulinumtoxinA-wlbg covers moderate-to-severe glabellar lines in adults. The UK under-75 wording is not substituted for it.[1]
ARTG 370012; the current register names Hugel Australia. The original 2022 decision named CROMA.[4][5]
Studies worth a closer look.#
Why the definition of “responder” matters.
Compare endpoint definitions before comparing percentages.
Follow the evidence.#
Retrieved 6 September 2026. A retrieval date does not establish that an older document is the latest approved revision. Studies marked “abstract” have not completed full-text appraisal.
- [1] LETYBO US prescribing information ↗Hugel / DailyMed · label · Document accessed · Document: Revised February 2024 · Checked 2026-09-06
- [2] Letybo 50 units Summary of Product Characteristics ↗Hugel / emc · label · Document accessed · Document: December 2025 · Checked 2026-09-06
- [3] Letybo German Fachinformation ↗Hugel / Fachinfo · label · Document accessed · Checked 2026-09-06
- [4] LETYBO 50 U — ARTG 370012 ↗Therapeutic Goods Administration · regulator · Document accessed · Checked 2026-09-06
- [5] Letybo Australian approval decision ↗Therapeutic Goods Administration · regulator · Document accessed · Document: December 2022 · Checked 2026-09-06
- [6] Mueller et al. — letibotulinumtoxinA phase III trial ↗Aesthetic Surgery Journal, 2022 · PMID 35092418 · study · Abstract accessed · Checked 2026-09-06
Cite this monograph#
Aesthetic Pass. Letybo. Product Atlas research edition 2026.09.06.1. https://aestheticpass.com/products/monographs/letybo/